The AIDS Research Consortium of Atlanta will close this year, after a gratifying 32 years of community-based research. We thank you for the honor and privilege of serving this community, and allowing us to figh...
Atlanta is one of 50 cities conducting a test study to find out that very thing.
The AIDS Research Consortium of Atlanta (ARCA) and the Center for Health Law and Policy Innovation (CHLPI) at Harvard Law School have filed a federal complaint alleging that insurance companies Cigna and Humana...
Did you know that people with HIV can live a normal—or even longer—lifespan if they get on treatment early and take it consistently? This awesome news is made possible by potent drugs that suppress HIV to low l...
This is our time. The time to end the AIDS epidemic in our community is now. Now we have effective treatment capable of preventing progression to AIDS in people with HIV, often allowing them to live a normal...
Ask any HIV researcher, employee of an HIV/AIDS organization or HIV activist what the most significant development in eliminating the virus in the last several years has been, and odds are they will say Pre-Exp...
Founded in 1988, the AIDS Research Consortium of Atlanta is one of Atlanta’s oldest continuously operating HIV/AIDS service organizations.
The agency learned in mid-September it would be forced from its home on Ponce de Leon Avenue after its building was purchased by a real estate developer who planned to build new residential properties.
The move to ARCA’s new location at 440 Ralph McGill Blvd. has been challenging, Dr. Melanie Thompson, ARCA executive director, told GA Voice.
“We were given about eight weeks, but it took us a long time to find a place where we wanted to live, given all the different constraints,” Thompson said. “We had been in our old place 22 years. You can imagine how much stuff accumulates over 22 years.”
The AIDS Research Consortium of Atlanta is being forced out of its office space on Ponce de Leon Avenue after the facility it has rented for 22 years was sold to real estate developers, the organization recently announced via its Facebook page.
ARCA, founded in 1988, focuses on HIV treatment and prevention research, as well as free HIV/STD testing services. Thousands of Atlantans have participated in more than 75 trials at ARCA, according to its website. “Our trials have contributed to the licensing by the FDA of 25 HIV/AIDS therapies that have been responsible for a dramatic increase in the length and quality of life for persons with HIV,” the agency states.
ARCA's currently facilities are located at 131 Ponce de Leon Ave., NE, between Ponce and North Avenue. The organization has been given until Oct. 22 to vacate the current space and needs some $10,000 to make the move happen, the group announced.
GeoVax Labs, an Atlanta-based biotechnology company, today announced a major milestone in its quest to eliminate the HIV virus, as the first patient has been inoculated with the company's HIV/AIDS vaccine following success in post-vaccine viral control in primates.
The company's vaccine is aimed at stimulating the body's immune system to resist the spread of infection.
"Dosing the first study participant marks a major milestone for our Phase 1/2 clinical trial. We are pleased to have the AIDS Research Consortium of Atlanta, the Alabama Vaccine Research Center at the University of Alabama, Birmingham, and the AIDS Research Alliance of Los Angeles participating in the trial,” said Robert McNally, president and CEO of GeoVax Labs, in a prepared statement.
“These three trial sites are actively seeking persons who are interested in and fit the criteria for the study," McNally added.
Dine Out for ARCA proceeds benefit HIV research
The AIDS Research Consortium of Atlanta is currently seeking 10 to 12 volunteers to help test the safety of a vaccine that shows the potential of reversing HIV viral loads in HIV-positive individuals.
The 77-week trial of a vaccine from GeoVax, a biotechnology company based in Smyrna, Ga., that specializes in developing an HIV vaccine, is the first of its kind.
This study is “the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.,” according to a May 18 press release from ARCA.